Comparative Pharmacology
Head-to-head clinical analysis: GLUMETZA versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUMETZA versus RIOMET ER.
GLUMETZA vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin hydrochloride, a biguanide, improves glucose tolerance in type 2 diabetes mellitus by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity (increasing peripheral glucose uptake and utilization).
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial: 500 mg orally once daily with evening meal; increase by 500 mg weekly based on tolerability. Maximum: 2000 mg once daily with evening meal. Extended-release formulation.
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
6.2 hours (terminal) in healthy adults; prolonged in renal impairment (e.g., 18 hours in CrCl <30 mL/min)
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
Renal (90% as unchanged drug); fecal (minor, <5%)
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic